Absci Corp (ABSI)
5.15
+0.17
(+3.41%)
USD |
NASDAQ |
May 03, 11:27
Absci Cash from Financing (TTM): -4.483M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -4.483M |
September 30, 2023 | -1.855M |
June 30, 2023 | -1.852M |
March 31, 2023 | 5.191M |
December 31, 2022 | 5.237M |
September 30, 2022 | 2.548M |
June 30, 2022 | 211.86M |
Date | Value |
---|---|
March 31, 2022 | 205.56M |
December 31, 2021 | 336.19M |
September 30, 2021 | 401.88M |
June 30, 2021 | 193.18M |
March 31, 2021 | 199.98M |
December 31, 2020 | 70.97M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-4.483M
Minimum
Dec 2023
401.88M
Maximum
Sep 2021
124.95M
Average
70.97M
Median
Dec 2020
Cash from Financing (TTM) Benchmarks
Amgen Inc | 21.05B |
Eli Lilly and Co | 2.772B |
Creative Medical Technology Holdings Inc | -0.271M |
HOOKIPA Pharma Inc | 65.67M |
Recursion Pharmaceuticals Inc | 140.13M |